title: Budesonide for Crohn's disease.
abstract: Crohn's disease is characterized by recurrent transmural inflammation of the gastrointestinal tract, most commonly, the terminal ileum and the colon. Therapy is aimed at breaking the cycle of inflammation by inducing and maintaining remission. Current effective therapies include systemic corticosteroids, but this class of drugs is associated with a variety of adverse effects, which may lead to significant morbidity and even mortality. Budesonide, a potent corticosteroid designed to have location specific delivery to the gastrointestinal tract, has limited systemic bioavailability largely due to its extensive first pass metabolism and has been demonstrated to be a safer alternative to conventional corticosteroids and of proven efficacy in the induction of remission in mild to moderate Crohn's disease. However, budesonide is not effective in maintaining remission in patients with Crohn's disease.
authors.affiliation: Mount Sinai Hospital, C/O Room 445, 600 University Avenue, Toronto, Ontario, M5G 1X5, Canada.
authors.forename: Cynthia H
authors.initials: CH
authors.lastname: Seow
authors.forename: Eric I
authors.initials: EI
authors.lastname: Benchimol
authors.forename: A Hillary
authors.initials: AH
authors.lastname: Steinhart
authors.forename: Anne M
authors.initials: AM
authors.lastname: Griffiths
authors.forename: Anthony R
authors.initials: AR
authors.lastname: Otley
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans
chemical_list: D000893:Anti-Inflammatory Agents; D019819:Budesonide